Want to see SE:MODTX full AI Analyst Report?

Modus Therapeutics Holding AB (MODTX) Price & Analysis

0 Followers

MODTX Stock Chart & Stats

kr0.30

-kr0.02(-1.23%)

At close: Mar 06 4:00 PM EST

kr0.30

-kr0.02(-1.23%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr5.00

Previous CloseN/A

Volume636.00

Average Volume (3M)841.43K

Market Cap

kr45.12M

Enterprise Valuekr30.08M

Total Cash (Recent Filing)kr6.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume409,277

30 Day Avg. Volume841,432

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageZero reported debt across 2023–2025 materially lowers fixed financing costs and bankruptcy risk, giving management durable flexibility to allocate scarce capital toward clinical development. Over a 2–6 month horizon this reduces immediate solvency pressure and supports program execution.

Focused Clinical-Stage PipelineA clear, clinical-stage focus on sickle cell microcirculation and vaso-occlusive complications positions the company in a defined rare-disease niche. This concentrated strategy enhances potential for orphan/regulatory incentives, strategic partnerships, and durable differentiation versus broad drug developers.

Improved Equity Base (Recent Recapitalization)Reported equity of ~SEK 9.1m in 2025 indicates recent recapitalization that provides a nearer-term buffer to fund clinical activities. While historically volatile, positive equity reduces immediate solvency risk and extends runway sufficiently to advance programs in the medium term.

Bears Say

Persistent Cash BurnOperating and free cash flow have been negative every year and worsened to roughly -SEK 18.1m in 2025, creating a structural funding imperative. Continued cash burn shortens runway, increases the likelihood of dilutive financing, and constrains ability to self-fund trials.

Pre-Revenue Business ModelThe company has been pre-revenue from 2020–2025, meaning no internal cash generation to support operations or commercialization. This structural lack of revenue increases reliance on external capital or partners and extends the timeline to sustainable margins and positive cash flow.

Sustained Losses And Negative ROEConsistent net losses (net loss ~-SEK 18.5m in 2025) and strongly negative return on equity reflect limited ability to generate returns from invested capital. This undermines reinvestment capacity, elevates investor scrutiny, and raises the probability of future dilutive financing rounds.

MODTX FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was kr0.21 and its highest was kr5.00 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is kr45.12M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 45 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -kr0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.027.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -kr0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.065%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in SE:MODTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.